
The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved that uses gene-editing technology. Casgevy, developed by Vertex Pharmaceuticals of Boston and CRISPR Therapeutics of Switzerland, is the first medicine available in the United States to treat a genetic disease using the… read on > read on >